Targeting mTOR Complexes in Ovarian Cancer
Seiji Mabuchi*, Tomoyuki Sasano and Mahiru Kawano
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Japan
- *Corresponding Author:
- Seiji Mabuchi, M.D., Ph.D.
Department of Obstetrics and Gynecology
Osaka University Graduate School of Medicine
2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
E-mail: [email protected]
Received Date: April 18, 2014; Accepted Date: June 19, 2014; Published Date: June 23, 2014
Citation: Mabuchi S, Sasano T, Kawano M (2014) Targeting mTOR Complexes in Ovarian Cancer. J Cancer Sci Ther 6:211-216. doi: 10.4172/1948-5956.1000274
Copyright: © 2014 Mabuchi S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The mammalian (mechanistic) target of rapamycin (mTOR) is a serine/threonine kinase that plays a key role in cell growth and proliferation and is regarded as an attractive therapeutic target for cancer therapy. Preclinical investigations have suggested that mTOR complex 1 (mTORC1) and mTORC2 are frequently activated in epithelial ovarian cancer, especially in clear cell carcinoma of the ovary. In mouse models of ovarian cancer, mTORC1 inhibitors have demonstrated promising antitumor activity against ovarian cancer both in the setting of monotherapy and when used in combination with cytotoxic agents. Based on these promising preclinical findings, mTORC1 inhibitors are currently being evaluated in phase I/II trials involving ovarian cancer patients. In an effort to overcome resistance to mTORC1 inhibitors, novel mTOR kinase inhibitors (TORKinib) that inhibit both mTORC1 and mTORC2 have recently been developed. In this report, we review the scientific rationale and evidence for the potential clinical benefits provided by mTOR inhibitors in patients with epithelial ovarian cancer.